

# Supplementary Documents [IFRS]

## Financial results for the fiscal year 2023 (FY2023)

### Astellas Pharma Inc.

- FY2023 Financial Results
  - For the year ended March 31, 2024
  - Three months ended March 31, 2024
- Pipeline list

#### Cautionary Notes

*In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.*

**[For the year ended March 31, 2024]**

1. Consolidated Results (Full Basis)

Unit: B¥

	FY22 Full Year	FY23 Full Year	Change	Change (%)
Revenue	1,518.6	1,603.7	85.1	5.6%
Cost of sales	288.4	292.5	4.1	1.4%
Ratio to Revenue	19.0%	18.2%		
Gross profit	1,230.3	1,311.2	80.9	6.6%
SG&A expenses	630.3	740.1	109.8	17.4%
Ratio to Revenue	41.5%	46.2%		
XTANDI co-promotion fee in the United States	175.5	194.9	19.4	11.0%
Personnel expenses	211.4	237.0	25.6	12.1%
Advertising and Sales Promotion and Other	243.4	308.2	64.9	26.6%
R&D expenses	276.1	294.2	18.1	6.5%
Ratio to Revenue	18.2%	18.3%		
Amortisation of intangible assets	38.4	98.8	60.4	157.1%
Gain on divestiture of intangible assets	0.2	9.7	9.5	-
Share of profit (loss) of investments accounted for using equity method	1.3	-3.2	-4.4	-351.1%
Other income	3.6	8.7	5.0	138.7%
Fair value remeasurements on contingent consideration	2.3	2.6	0.3	12.8%
Other expenses	157.5	167.8	10.3	6.5%
Impairment losses	84.6	78.9	-5.7	-6.7%
Restructuring costs	4.5	25.4	20.9	463.3%
Fair value remeasurements on contingent consideration	53.1	24.7	-28.4	-53.5%
Replacement awards with business combination*	-	33.4	33.4	-
Operating profit	133.0	25.5	-107.5	-80.8%
Ratio to Revenue	8.8%	1.6%		
Finance income	8.1	11.5	3.3	41.2%
Finance expenses	8.8	12.0	3.2	36.7%
Profit before tax	132.4	25.0	-107.4	-81.1%
Ratio to Revenue	8.7%	1.6%		
Income tax expense	33.6	7.9	-25.7	-76.5%
Profit	98.7	17.0	-81.7	-82.7%
Ratio to Revenue	6.5%	1.1%		
Comprehensive income	205.3	205.6	0.3	0.1%

(\*) Payment for Iveric Bio's unvested share-based payments, such as share options

FY23 Revised Forecasts	Forecasts	
	FY24 Full Year	Change from FY23 (%)
1,562.0	1,650.0	2.9%
	326.0	11.5%
	19.8%	
731.0	757.0	2.3%
46.8%	45.9%	
187.0	189.0	-3.0%
286.0	317.0	7.8%
18.3%	19.2%	
13.0	48.0	88.1%
0.8%	2.9%	
12.0	43.0	72.2%
0.8%	2.6%	
3.0	30.0	76.0%
0.2%	1.8%	

2. Consolidated Results (Core Basis Old Definition)

Unit: B¥

	FY22 Full Year	FY23 Full Year	Change	Change (%)	FY23 Revised Forecasts
Revenue	1,518.6	1,603.7	85.1	5.6%	1,562.0
Cost of sales	288.4	292.5	4.1	1.4%	
Ratio to Revenue	19.0%	18.2%			
Gross profit	1,230.3	1,311.2	80.9	6.6%	
SG&A expenses	630.3	740.1	109.8	17.4%	731.0
Ratio to Revenue	41.5%	46.2%			46.8%
XTANDI co-promotion fee in the United States	175.5	194.9	19.4	11.0%	187.0
Personnel expenses	211.4	237.0	25.6	12.1%	
Advertising and Sales Promotion and Other	243.4	308.2	64.9	26.6%	
R&D expenses	276.1	294.2	18.1	6.5%	286.0
Ratio to Revenue	18.2%	18.3%			18.3%
Amortisation of intangible assets	38.4	98.8	60.4	157.1%	
Gain on divestiture of intangible assets	0.2	9.7	9.5	-	
Share of profit (loss) of investments accounted for using equity method	1.3	-3.2	-4.4	-351.1%	
Operating profit	286.9	184.6	-102.3	-35.6%	164.0
Ratio to Revenue	18.9%	11.5%			10.5%
Finance income	8.1	11.5	3.3	41.2%	
Finance expenses	8.8	12.0	3.2	36.7%	
Profit before tax	286.2	184.1	-102.1	-35.7%	
Ratio to Revenue	18.8%	11.5%			
Income tax expense	61.6	33.1	-28.5	-46.3%	
Profit	224.6	151.0	-73.6	-32.8%	127.0
Ratio to Revenue	14.8%	9.4%			8.1%

3. Consolidated Results (Core Basis New Definition)

Unit: B¥

	FY22 Full Year	FY23 Full Year	Change	Change (%)
Revenue	1,518.6	1,603.7	85.1	5.6%
Cost of sales	288.4	292.5	4.1	1.4%
Ratio to Revenue	19.0%	18.2%		
Gross profit	1,230.3	1,311.2	80.9	6.6%
SG&A expenses	630.3	740.1	109.8	17.4%
Ratio to Revenue	41.5%	46.2%		
XTANDI co-promotion fee in the United States	175.5	194.9	19.4	11.0%
Personnel expenses	211.4	237.0	25.6	12.1%
Advertising and Sales Promotion and Other	243.4	308.2	64.9	26.6%
R&D expenses	276.1	294.2	18.1	6.5%
Ratio to Revenue	18.2%	18.3%		
Operating profit	323.9	276.9	-47.0	-14.5%
Ratio to Revenue	21.3%	17.3%		
Finance income	8.1	11.5	3.3	41.2%
Finance expenses	8.8	12.0	3.2	36.7%
Profit before tax	323.2	276.3	-46.9	-14.5%
Ratio to Revenue	21.3%	17.2%		
Income tax expense	72.1	53.1	-18.9	-26.3%
Profit	251.1	223.2	-27.9	-11.1%
Ratio to Revenue	16.5%	13.9%		

Forecasts		Change from FY23
FY24 Full Year	Change (%)	
1,650.0	2.9%	
326.0	11.5%	
19.8%		
757.0	2.3%	
45.9%		
189.0	-3.0%	
317.0	7.8%	
19.2%		
250.0	-9.7%	
15.2%		
186.0	-16.7%	
11.3%		

The definition of core-basis will be changed from FY2024. In addition to the old definition's adjustments, 'Amortisation of intangible assets', 'Gain on divestiture of intangible assets' and 'Share of profit (loss) of investments accounted for using equity method' will be newly excluded as new adjustment items. All figures above reflect this change.

4. Exchange Rate

Unit: yen

	FY22 Ave.	FY23 Ave.	FY22 End	FY23 End
USD/Yen	135	145	133	151
EUR/Yen	141	157	144	163

FY23 Revised Forecasts
140
152

Forecasts FY24 Full Year
145
155

\* Fx impacts: Revenue +96.3 billion yen and Core operating profit (Old definition) +19.1 billion yen

5. Reconciliation of Full Basis to Core Basis (Old Definition)

Unit: B¥

	FY22 Full year			FY23 Full year		
	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
<b>Revenue</b>	<b>1,518.6</b>	-	<b>1,518.6</b>	<b>1,603.7</b>	-	<b>1,603.7</b>
Cost of sales	288.4	-	288.4	292.5	-	292.5
<b>Gross profit</b>	<b>1,230.3</b>	-	<b>1,230.3</b>	<b>1,311.2</b>	-	<b>1,311.2</b>
SG&A expenses	630.3	-	630.3	740.1	-	740.1
R&D expenses	276.1	-	276.1	294.2	-	294.2
Amortisation of intangible assets	38.4	-	38.4	98.8	-	98.8
Gain on divestiture of intangible assets	0.2	-	0.2	9.7	-	9.7
Share of profit (loss) of investments accounted for using equity method	1.3	-	1.3	-3.2	-	-3.2
Other income *	3.6	-3.6	-	8.7	-8.7	-
Other expenses *	157.5	-157.5	-	167.8	-167.8	-
<b>Operating profit</b>	<b>133.0</b>	<b>153.9</b>	<b>286.9</b>	<b>25.5</b>	<b>159.1</b>	<b>184.6</b>
Finance income	8.1	-	8.1	11.5	-	11.5
Finance expenses	8.8	-	8.8	12.0	-	12.0
<b>Profit before tax</b>	<b>132.4</b>	<b>153.9</b>	<b>286.2</b>	<b>25.0</b>	<b>159.1</b>	<b>184.1</b>
Income tax expense	33.6	28.0	61.6	7.9	25.2	33.1
<b>Profit</b>	<b>98.7</b>	<b>125.9</b>	<b>224.6</b>	<b>17.0</b>	<b>133.9</b>	<b>151.0</b>

\* "Other income" and "Other expenses" are excluded from Core basis results.

"Other income" and "Other expenses" include gain/loss on sale and disposal of property, plant and equipment, impairment losses, restructuring costs, litigation costs and foreign exchange gains/losses, etc.

## 6. Revenue by Region

Unit: B¥

		FY22 Full Year	FY23 Full Year	Change	Change (%)
Revenue		1,518.6	1,603.7	85.1	5.6%
Japan		262.3	270.1	7.8	3.0%
	Ratio to Revenue	17.3%	16.8%		
United States		652.4	663.1	10.7	1.6%
	Ratio to Revenue	43.0%	41.3%		
Established Markets		359.8	415.6	55.8	15.5%
	Ratio to Revenue	23.7%	25.9%		
Greater China		80.0	88.5	8.5	10.6%
	Ratio to Revenue	5.3%	5.5%		
International Markets		143.3	159.1	15.7	11.0%
	Ratio to Revenue	9.4%	9.9%		
Others		20.7	7.3	-13.4	-64.8%
	Ratio to Revenue	1.4%	0.5%		

FY23 Revised Forecasts
1,562.0
278.4
17.8%
645.5
41.3%
397.9
25.5%
85.1
5.4%
149.8
9.6%
5.3
0.3%

Forecasts		Change from FY23
FY24 Full Year	Change (%)	
1,650.0		2.9%
278.7		3.2%
16.9%		
670.0		1.0%
40.6%		
437.4		5.2%
26.5%		
70.5		-20.3%
4.3%		
187.0		17.6%
11.3%		
6.5		-11.2%
0.4%		

- Established Markets: Europe, Canada, etc.

- Greater China: China, Hong Kong, Taiwan

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Australia, Export sales, etc.

- From FY2023 Q1, the commercial segment of some countries were changed from International Markets to Established Markets. All figures above reflect this change.

- From FY2024, the commercial segment of Taiwan will be changed from Greater China to International Markets. Figures of FY24 forecasts above reflect this change.

## 7. Per Share Information

	FY22 Full Year	FY23 Full Year
The number of shares issued (thousand)	1,809,663	1,809,663
Treasury Shares (thousand)	12,900	16,561
The number of shares issued after deducting Treasury Shares (thousand)	1,796,762	1,793,101
Earnings per share (yen)	54.24	9.51
Earnings per share (yen) core basis	137.98	124.46
Dividend per share (yen)	60	70
Return on Equity (%)	6.7%	1.1%
Dividend on Equity (%)	7.3%	8.1%

FY23 Revised Forecasts
32.34
70.82
70

Forecasts	
FY24 Full Year	
16.73	
103.73	
74	

- The numbers of shares stated in the business report are presented by disregarding any number of shares less than the specified units.

- The numbers of Earnings per share (yen) core basis are calculated based on the new definition of core basis.

## 8. Investment in Property, Plant and Equipment

### Depreciation/Amortisation

Unit: B¥

	FY22 Full Year	FY23 Full Year	Change	Change (%)
Investment in Property, Plant and Equipment	36.6	35.4	-1.1	-3.0%
Depreciation (PP&E)	40.0	42.4	2.4	6.0%
Amortisation of Intangible Assets (incl. software, etc.)	65.7	115.4	49.7	75.7%

FY23 Revised Forecasts
39.0
43.0
112.0

Forecasts		Change from FY23
FY24 Full Year	Change (%)	
55.0		55.2%
42.0		-1.0%
161.0		39.5%

- Investment in Property, Plant and Equipment does not include right-of-use asset.

9. Sales of major products

1) Global

Unit: B¥

	FY22 Full Year	FY23 Full Year	Change	Change (%)	FY23 Revised Forecasts	Forecasts	
						FY24 Full Year	Change (%)
XTANDI	661.1	750.5	89.3	13.5%	719.8	757.0	0.9%
Japan	54.7	56.7	2.0	3.7%	58.2	58.9	3.9%
United States	341.8	379.7	37.9	11.1%	363.8	369.1	-2.8%
Established Markets	197.9	231.6	33.6	17.0%	221.8	236.4	2.1%
Greater China	11.1	16.9	5.9	53.0%	16.1	14.7	-13.3%
International Markets	55.6	65.5	9.9	17.9%	60.0	77.9	18.9%
PADCEV	44.4	85.4	40.9	92.1%	85.2	151.2	77.2%
Japan	8.4	8.5	0.1	1.5%	9.9	11.3	33.2%
United States	29.2	60.7	31.5	108.1%	60.2	107.5	77.3%
Established Markets	6.8	14.7	7.9	116.9%	14.0	28.2	91.4%
Greater China	-	0.5	0.5	-	0.2	0.7	41.8%
International Markets	0.1	0.9	0.8	841.2%	0.8	3.4	276.6%
XOSPATA	46.6	55.1	8.5	18.3%	55.2	60.0	8.9%
Japan	4.3	4.4	0.0	1.1%	4.6	5.0	14.2%
United States	25.5	28.6	3.0	11.9%	29.5	29.2	2.2%
Established Markets	12.1	15.2	3.1	25.7%	14.5	16.8	11.0%
Greater China	2.5	3.2	0.8	31.7%	2.9	3.5	7.8%
International Markets	2.2	3.8	1.6	70.8%	3.8	5.5	45.3%
VEOZAH	-	7.3	7.3	-	7.1	28.3	287.8%
United States	-	7.2	7.2	-	7.1	25.8	260.3%
Established Markets	-	0.1	0.1	-	0.0	2.0	-
IZERVAY	-	12.1	12.1	-	11.0	46.4	282.6%
United States	-	12.1	12.1	-	11.0	46.1	280.0%
EVRENZO	3.2	4.5	1.3	41.0%	5.1	4.7	3.0%
Japan	2.4	2.1	-0.3	-13.1%	2.2	1.7	-17.4%
Established Markets	0.6	2.0	1.3	213.2%	2.0	2.6	31.8%
International Markets	0.2	0.5	0.3	176.9%	0.9	0.3	-26.7%
BETANIS/MYRBETRIQ/BETMIGA	188.6	198.1	9.5	5.0%	194.4	118.0	-40.4%
Japan	33.5	27.4	-6.2	-18.4%	29.0	25.7	-6.1%
United States	96.5	101.3	4.8	5.0%	99.3	16.6	-83.6%
Established Markets	42.9	51.3	8.4	19.6%	49.2	57.1	11.4%
Greater China	3.9	3.9	-0.0	-0.9%	3.6	1.2	-69.2%
International Markets	11.8	14.2	2.5	21.0%	13.3	17.4	22.0%
PROGRAF	198.8	203.1	4.3	2.2%	196.5	191.8	-5.6%
Japan	35.6	29.5	-6.1	-17.1%	29.8	25.3	-14.4%
United States	10.7	10.0	-0.7	-7.0%	10.3	10.1	0.9%
Established Markets	69.8	73.8	4.1	5.8%	70.7	69.6	-5.8%
Greater China	46.8	49.2	2.3	5.0%	48.0	41.3	-15.9%
International Markets	35.8	40.6	4.7	13.2%	37.6	45.5	12.2%
VESICARE	15.9	14.6	-1.3	-8.1%	13.9	13.3	-8.6%

- FY2022 sales of products in Japan are shown in a gross sales basis. FY2023 sales and forecasts are shown in a net sales basis, as in other regions.

- Established Markets: Europe, Canada, etc.

- Greater China: China, Hong Kong, Taiwan

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Australia, Export sales, etc.

- From FY2023 Q1, the commercial segment of some countries were changed from International Markets to Established Markets. All figures above reflect this change.

- PADCEV (United States): Co-promotion revenue from Pfizer

- Astellas' EVRENZO territories: Japan, Europe, the Commonwealth of Independent States, Middle East, South Africa, etc.

- From FY2024, the commercial segment of Taiwan will be changed from Greater China to International Markets. Figures of FY24 forecasts above reflect this change.

- VEOZAH: Approved as "VEOZA" in Europe

2) Revenue by region - FY2022 sales of products in Japan are shown in a gross sales basis. FY2023 sales and forecasts are shown in a net sales basis, as in other regions.

(1) Japan

		Unit: B¥					Forecasts		Change from FY23
<Global>		FY22 Full Year	FY23 Full Year	Change	Change (%)	FY23 Revised Forecasts	FY24 Full Year	Change (%)	
XTANDI		54.7	56.7	2.0	3.7%	58.2	58.9	3.9%	
PADCEV		8.4	8.5	0.1	1.5%	9.9	11.3	33.2%	
XOSPATA		4.3	4.4	0.0	1.1%	4.6	5.0	14.2%	
EVRENZO		2.4	2.1	-0.3	-13.1%	2.2	1.7	-17.4%	
BETANIS		33.5	27.4	-6.2	-18.4%	29.0	25.7	-6.1%	
PROGRAF (Including GRACEPTOR)		35.6	29.5	-6.1	-17.1%	29.8	25.3	-14.4%	
HARNAL		1.8	1.3	-0.5	-27.7%	1.4			
<Main products>									
SUGLAT [Family]		30.3	27.9	-2.4	-8.0%	29.1	27.3	-2.2%	
SUJANU		12.3	11.0	-1.3	-10.6%				
REPATHA		6.4	6.7	0.3	5.2%				
LINZESS		7.0	6.4	-0.6	-8.8%	7.2			
BLINCYTO		7.9	11.2	3.4	42.6%				
EVENITY		42.1	48.8	6.7	15.9%				
SMYRAF		2.5	2.4	-0.1	-3.6%	2.7			
Vaccines		5.5	4.6	-0.8	-15.1%	5.1			
CIMZIA		11.2	10.0	-1.2	-11.1%	10.1	10.1	0.9%	
Total Rx Sales In Japanese market		260.1	269.0	9.0	3.5%	277.3	278.0	3.3%	

(2) United States

		Unit: M\$					Forecasts		Change from FY23
Revenue		FY22 Full Year	FY23 Full Year	Change	Change (%)	FY23 Revised Forecasts	FY24 Full Year	Change (%)	
XTANDI		4,816	4,587	-228	-4.7%	4,594	4,621	0.7%	
PADCEV		2,523	2,627	104	4.1%	2,589	2,545	-3.1%	
VEOZAH		215	420	204	95.0%	428	742	76.7%	
XOSPATA		188	198	9	4.9%	210	201	1.9%	
IZERVAY		-	50	50	-	50	178	259.2%	
MYRBETRIQ		-	84	84	-	79	318	278.8%	
PROGRAF		712	701	-11	-1.6%	707	114	-83.7%	
AMBISOME		79	69	-10	-12.8%	74	70	0.6%	
CRESEMBA		118	106	-12	-10.6%	100			
LEXISCAN		228	259	31	13.7%	272	310	19.7%	
		725	65	-660	-91.0%	75			



(3) Established Markets

Unit: M€

	FY22 Full Year	FY23 Full Year	Change	Change (%)
Revenue	2,554	2,651	98	3.8%
XTANDI	1,405	1,477	73	5.2%
PADCEV	48	94	46	95.0%
XOSPATA	86	97	11	13.0%
VEOZA	-	1	1	-
EVRENZO	4	13	8	181.6%
BETMIGA	304	327	23	7.5%
PROGRAF	495	471	-24	-4.9%
OMNIC	69	67	-2	-3.5%

FY23 Revised Forecasts
2,623
1,462
93
96
0
13
324
466
65

Forecasts		Change from FY23
FY24 Full Year	Change (%)	
2,822	6.4%	
1,525	3.2%	
182	93.5%	
109	12.3%	
13	-	
17	33.3%	
368	12.7%	
449	-4.7%	

- Established Markets: Europe, Canada, etc.

- From FY2023 Q1, the commercial segment of some countries were changed from International Markets to Established Markets. All figures above reflect this change.

(4) Greater China

Unit: B¥

	FY22 Full Year	FY23 Full Year	Change	Change (%)
Revenue	80.0	88.5	8.5	10.6%
XTANDI	11.1	16.9	5.9	53.0%
PADCEV	-	0.5	0.5	-
XOSPATA	2.5	3.2	0.8	31.7%
BETMIGA	3.9	3.9	-0.0	-0.9%
PROGRAF	46.8	49.2	2.3	5.0%
HARNAL	8.2	8.8	0.5	6.6%
FEBURIC	3.4	3.6	0.2	6.3%

FY23 Revised Forecasts
85.1
16.1
0.2
2.9
3.6
48.0
8.7
3.3

Forecasts		Change from FY23
FY24 Full Year	Change (%)	
70.5	-20.3%	
14.7	-13.3%	
0.7	41.8%	
3.5	7.8%	
1.2	-69.2%	
41.3	-15.9%	

- Greater China: China, Hong Kong, Taiwan

- From FY2024, the commercial segment of Taiwan will be changed from Greater China to International Markets. Figures of FY24 forecasts above reflect this change.

(5) International Markets

Unit: B¥

	FY22 Full Year	FY23 Full Year	Change	Change (%)
Revenue	143.3	159.1	15.7	11.0%
XTANDI	55.6	65.5	9.9	17.9%
PADCEV	0.1	0.9	0.8	841.2%
XOSPATA	2.2	3.8	1.6	70.8%
EVRENZO	0.2	0.5	0.3	176.9%
BETMIGA	11.8	14.2	2.5	21.0%
PROGRAF	35.8	40.6	4.7	13.2%
HARNAL	17.9	18.5	0.6	3.3%

FY23 Revised Forecasts
149.8
60.0
0.8
3.8
0.9
13.3
37.6
18.7

Forecasts		Change from FY23
FY24 Full Year	Change (%)	
187.0	17.6%	
77.9	18.9%	
3.4	276.6%	
5.5	45.3%	
0.3	-26.7%	
17.4	22.0%	
45.5	12.2%	
20.9	13.1%	

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Australia, Export sales, etc.

- From FY2023 Q1, the commercial segment of some countries were changed from International Markets to Established Markets. All figures above reflect this change.

- From FY2024, the commercial segment of Taiwan will be changed from Greater China to International Markets. Figures of FY24 forecasts above reflect this change.

## 10. Consolidated statements of financial position

Unit: B¥

	FY22 End	FY23 End	Change
<b>Assets</b>	<b>2,456.5</b>	<b>3,569.6</b>	<b>1,113.1</b>
<b>Non-current assets</b>	<b>1,406.6</b>	<b>2,374.9</b>	<b>968.3</b>
Property, plant and equipment	286.5	293.7	7.3
Goodwill	328.4	418.7	90.3
Intangible assets	562.5	1,453.8	891.3
Trade and other receivables	24.2	20.0	-4.1
Investments accounted for using equity method	12.7	15.7	3.0
Deferred tax assets	84.2	45.6	-38.6
Other financial assets	97.9	108.7	10.8
Other non-current assets	10.3	18.6	8.3
<b>Current assets</b>	<b>1,050.0</b>	<b>1,194.7</b>	<b>144.8</b>
Inventories	174.4	248.7	74.4
Trade and other receivables	428.0	535.0	107.0
Income tax receivable	17.8	13.1	-4.8
Other financial assets	19.8	28.8	9.0
Other current assets	32.4	32.2	-0.2
Cash and cash equivalents	376.8	335.7	-41.2
Assets held for sale	0.7	1.2	0.5

Unit: B¥

	FY22 End	FY23 End	Change
<b>Equity and Liabilities</b>	<b>2,456.5</b>	<b>3,569.6</b>	<b>1,113.1</b>
<b>Equity</b>	<b>1,508.0</b>	<b>1,596.0</b>	<b>88.0</b>
<b>Equity attributable to owners of the parent</b>	<b>1,508.0</b>	<b>1,596.0</b>	<b>88.0</b>
Share capital	103.0	103.0	-
Capital surplus	181.3	184.1	2.8
Treasury shares	-25.1	-33.8	-8.7
Retained earnings	908.2	809.4	-98.8
Other components of equity	340.6	533.3	192.7
<b>Liabilities</b>	<b>948.6</b>	<b>1,973.6</b>	<b>1,025.1</b>
<b>Non-current liabilities</b>	<b>222.5</b>	<b>687.9</b>	<b>465.4</b>
Bonds and borrowings	50.0	447.7	397.7
Trade and other payables	4.2	2.2	-2.0
Deferred tax liabilities	6.0	51.3	45.3
Retirement benefit liabilities	24.8	24.7	-0.1
Provisions	6.5	7.4	0.8
Other financial liabilities	89.9	105.6	15.7
Other non-current liabilities	41.0	49.0	8.0
<b>Current liabilities</b>	<b>726.0</b>	<b>1,285.7</b>	<b>559.7</b>
Bonds and borrowings	75.0	472.3	397.3
Trade and other payables	140.2	185.2	45.0
Income tax payable	5.1	38.5	33.4
Provisions	17.9	15.7	-2.2
Other financial liabilities	105.1	97.6	-7.6
Other current liabilities	382.7	476.5	93.8

11. Employees

Number of employees

	FY22 End	FY23 End
Total	14,484	14,759

12. Shareholders

	FY22 End	FY23 End
Banks	39.6%	36.3%
Securities	5.0%	6.6%
Other companies	3.1%	3.4%
Foreign companies	43.3%	39.9%
Individuals and others	8.9%	13.7%
Treasury Stock*	0.0%	0.0%

\* Treasury Stock does not include shares owned by the executive compensation BIP (Board Incentive Plan) trust and ESOP (Employee Stock Ownership Plan) trust.

## [Three months ended March 31, 2024]

### 1. Consolidated Results (Full Basis)

Unit: B¥

	FY23							
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Revenue	375.0	-1.8%	392.1	3.1%	421.9	4.9%	414.6	17.0%
Cost of sales	68.9	-22.4%	74.4	18.5%	75.9	2.0%	73.2	17.6%
Ratio to Revenue	18.4%		19.0%		18.0%		17.7%	
Gross profit	306.0	4.5%	317.7	0.0%	346.0	5.6%	341.4	16.9%
SG&A expenses	168.2	9.6%	179.3	16.0%	199.5	22.4%	193.1	21.3%
Ratio to Revenue	44.8%		45.7%		47.3%		46.6%	
XTANDI co-promotion fee in the United States	44.6	3.4%	48.5	4.2%	53.2	9.5%	48.6	30.5%
Personnel expenses	57.4	12.0%	58.9	9.9%	61.6	19.5%	59.2	7.5%
Advertising and Sales Promotion and Other	66.3	12.2%	71.9	32.1%	84.7	34.6%	85.3	27.4%
R&D expenses	64.6	-12.7%	77.4	18.7%	74.4	11.2%	77.9	11.1%
Ratio to Revenue	17.2%		19.7%		17.6%		18.8%	
Amortisation of intangible assets	9.1	-15.6%	24.7	167.4%	32.4	252.4%	32.6	252.5%
Gain on divestiture of intangible assets	0.1	-68.5%	9.4	-	0.3	791.2%	-	-
Share of profit (loss) of investments accounted for using equity method	0.7	96.2%	-0.9	-	-0.2	-	-2.7	-
Other income	3.9	-76.0%	3.3	-	2.6	136.8%	0.4	-90.9%
Fair value remeasurements on contingent consideration	2.6	80.0%	0.1	-28.3%	0.5	-48.2%	0.2	-96.1%
Other expenses	23.1	-40.0%	38.8	989.9%	23.4	-16.3%	84.0	-20.5%
Impairment losses	10.5	-52.2%	2.7	263.4%	0.6	-63.0%	65.2	8.1%
Restructuring costs	1.4	-	1.4	29.8%	15.6	-	7.0	136.5%
Fair value remeasurements on contingent consideration	10.1	-35.8%	1.3	-	5.9	45.3%	8.1	-78.3%
Replacement awards with business combination*	-	-	32.6*	-	0.5	-	0.3	-
Operating profit	45.8	38.2%	9.4	-89.2%	19.0	-69.1%	-48.6	-
Ratio to Revenue	12.2%		2.4%		4.5%		-11.7%	
Finance income	3.8	307.2%	2.4	-33.4%	1.2	0.6%	4.1	68.8%
Finance expenses	2.7	13.5%	2.3	50.5%	2.8	1.0%	4.2	102.0%
Profit before tax	46.8	47.9%	9.5	-89.3%	17.3	-71.0%	-48.7	-
Ratio to Revenue	12.5%		2.4%		4.1%		-11.7%	
Income tax expense	13.7	99.8%	6.8	-60.5%	2.8	-75.3%	-15.4	-
Profit	33.1	33.5%	2.7	-96.3%	14.5	-70.0%	-33.3	-
Ratio to Revenue	8.8%		0.7%		3.4%		-8.0%	
Comprehensive income	134.5	0.1%	58.2	-46.8%	-78.7	-	91.6	-

(\*) Payment for Iveric Bio's unvested share-based payments, such as share options

(\*\*) In the third quarter, further facts came to light and additional analysis was performed. As a result, "Replacement awards with business combination" was adjusted retroactively.

2. Consolidated Results (Core Basis Old Definition)

Unit: B¥

		FY23							
		APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
		(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Revenue		375.0	-1.8%	392.1	3.1%	421.9	4.9%	414.6	17.0%
Cost of sales		68.9	-22.4%	74.4	18.5%	75.9	2.0%	73.2	17.6%
	Ratio to Revenue	18.4%		19.0%		18.0%		17.7%	
Gross profit		306.0	4.5%	317.7	0.0%	346.0	5.6%	341.4	16.9%
SG&A expenses		168.2	9.6%	179.3	16.0%	199.5	22.4%	193.1	21.3%
	Ratio to Revenue	44.8%		45.7%		47.3%		46.6%	
XTANDI co-promotion fee in the United States		44.6	3.4%	48.5	4.2%	53.2	9.5%	48.6	30.5%
Personnel expenses		57.4	12.0%	58.9	9.9%	61.6	19.5%	59.2	7.5%
Advertising and Sales Promotion and Other		66.3	12.2%	71.9	32.1%	84.7	34.6%	85.3	27.4%
R&D expenses		64.6	-12.7%	77.4	18.7%	74.4	11.2%	77.9	11.1%
	Ratio to Revenue	17.2%		19.7%		17.6%		18.8%	
Amortisation of intangible assets		9.1	-15.6%	24.7	167.4%	32.4	252.4%	32.6	252.5%
Gain on divestiture of intangible assets		0.1	-68.5%	9.4	-	0.3	791.2%	-	-
Share of profit (loss) of investments accounted for using equity method		0.7	96.2%	-0.9	-	-0.2	-	-2.7	-
Operating profit		64.9	17.4%	44.9	-50.2%	39.8	-54.9%	35.0	-34.2%
	Ratio to Revenue	17.3%		11.4%		9.4%		8.4%	
Finance income		3.8	307.2%	2.4	-33.4%	1.2	0.6%	4.1	68.8%
Finance expenses		2.7	13.5%	2.3	50.5%	2.8	1.0%	4.2	102.0%
Profit before Tax		66.0	22.6%	45.0	-51.2%	38.2	-56.0%	35.0	-34.8%
	Ratio to Revenue	17.6%		11.5%		9.0%		8.4%	
Income tax expense		14.2	77.7%	7.0	-61.0%	7.4	-58.1%	4.5	-75.0%
Profit		51.8	13.0%	38.0	-48.8%	30.7	-55.4%	30.5	-14.6%
	Ratio to Revenue	13.8%		9.7%		7.3%		7.4%	

### 3. Revenue by Region

Unit: B¥

		FY23							
		APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
		(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Revenue		375.0	-1.8%	392.1	3.1%	421.9	4.9%	414.6	17.0%
	Japan	68.3	2.2%	69.3	4.2%	73.5	3.1%	59.1	2.2%
	Ratio to Revenue	18.2%		17.7%		17.4%		14.2%	
	United States	150.0	-6.8%	156.7	-6.4%	174.7	1.1%	181.7	20.1%
	Ratio to Revenue	40.0%		40.0%		41.4%		43.8%	
	Established Markets	96.8	11.8%	102.3	15.0%	107.2	10.9%	109.2	24.7%
	Ratio to Revenue	25.8%		26.1%		25.4%		26.3%	
	Greater China	22.5	-2.7%	22.4	2.3%	22.4	11.4%	21.2	42.5%
	Ratio to Revenue	6.0%		5.7%		5.3%		5.1%	
	International Markets	34.7	2.4%	39.9	17.5%	44.2	21.6%	40.3	2.9%
	Ratio to Revenue	9.3%		10.2%		10.5%		9.7%	
	Others	2.6	-75.1%	1.6	-8.0%	0.0	-99.5%	3.1	-11.2%
	Ratio to Revenue	0.7%		0.4%		0.0%		0.7%	

- Established Markets: Europe, Canada, etc.

- Greater China: China, Hong Kong, Taiwan

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Australia, Export sales, etc.

- From FY2023 Q1, the commercial segment of some countries were changed from International Markets to Established Markets. All figures above reflect this change.

### 4. Investment in Property, Plant and Equipment Depreciation/Amortisation

Unit: B¥

	FY23							
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Investment in Property, Plant and Equipment	9.3	-20.1%	7.4	27.1%	6.1	-13.4%	12.6	5.0%
Depreciation (PP&E)	10.2	3.5%	10.1	2.2%	10.4	3.4%	11.7	14.4%
Amortisation of Intangible Assets (incl. software, etc.)	13.1	-51.7%	28.8	123.0%	36.6	182.7%	37.0	188.4%

- Investment in Property, Plant and Equipment does not include right-of-use asset.

5. Sales of major products

1) Global

Unit: B¥

		FY23							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
XTANDI		174.1	7.2%	186.9	10.2%	199.0	10.7%	190.5	27.6%
	Japan	14.4	2.3%	14.4	7.6%	15.3	3.4%	12.6	1.4%
	United States	86.8	3.4%	94.5	3.9%	103.6	9.9%	94.8	30.5%
	Established Markets	54.6	16.7%	57.5	14.9%	59.3	11.6%	60.2	25.6%
	Greater China	4.4	22.6%	5.7	135.3%	3.4	-11.4%	3.4	177.7%
	International Markets	13.8	-1.0%	14.8	15.2%	17.5	26.4%	19.5	29.8%
PADCEV		15.2	44.2%	17.5	71.0%	22.9	86.3%	29.8	161.6%
	Japan	2.2	13.1%	2.1	4.4%	2.2	-6.5%	2.0	-3.6%
	United States	10.5	43.0%	12.5	83.3%	16.0	104.1%	21.7	202.4%
	Established Markets	2.4	94.2%	2.7	99.3%	4.2	103.8%	5.4	154.6%
	Greater China	-	-	0.0	-	0.2	-	0.3	-
	International Markets	0.1	-	0.1	621.6%	0.3	442.2%	0.4	-
XOSPATA		13.0	24.2%	13.3	2.3%	15.0	16.9%	13.8	34.3%
	Japan	1.2	6.6%	1.1	4.2%	1.2	-7.1%	0.9	2.2%
	United States	7.1	20.2%	6.9	5.4%	7.1	-6.9%	7.5	37.2%
	Established Markets	3.3	24.4%	3.9	34.2%	4.0	23.4%	4.0	21.5%
	Greater China	0.6	22.9%	0.7	-65.4%	1.7	-	0.3	-
	International Markets	0.9	155.3%	0.8	36.4%	1.1	51.2%	1.1	78.8%
VEOZAH		0.6	-	0.7	-	2.3	-	3.7	-
	United States	0.6	-	0.7	-	2.3	-	3.6	-
	Established Markets	-	-	-	-	-	-	0.1	-
IZERVAY		-	-	1.2	-	4.1	-	6.9	-
	United States	-	-	1.2	-	4.1	-	6.9	-
EVRENZO		1.0	31.0%	1.1	34.1%	1.3	42.6%	1.2	55.8%
	Japan	0.6	-12.1%	0.5	-10.8%	0.6	-13.9%	0.4	-16.3%
	Established Markets	0.3	382.8%	0.4	179.2%	0.6	174.4%	0.6	222.3%
	International Markets	0.0	-	0.1	169.5%	0.1	437.6%	0.2	67.8%
BETANIS/MYRBETRIQ/BETMIGA		49.2	2.7%	46.6	2.5%	47.0	-1.3%	55.2	16.1%
	Japan	7.3	-21.3%	6.8	-16.5%	7.3	-18.3%	6.0	-17.1%
	United States	26.1	5.6%	22.7	-0.2%	21.6	-6.2%	31.0	18.9%
	Established Markets	11.5	14.0%	12.8	19.6%	13.2	14.0%	13.8	31.1%
	Greater China	1.0	-3.4%	0.9	-11.5%	1.0	-7.0%	1.1	20.8%
	International Markets	3.4	19.3%	3.5	18.0%	4.0	28.6%	3.4	17.7%
PROGRAF		49.1	-5.3%	51.0	5.0%	55.3	7.9%	47.7	1.2%
	Japan	8.0	-16.4%	7.3	-17.5%	8.2	-15.0%	6.0	-20.3%
	United States	2.4	-6.4%	2.6	-0.2%	2.7	-13.1%	2.3	-7.1%
	Established Markets	17.8	-0.6%	18.1	5.2%	19.2	5.4%	18.8	14.0%
	Greater China	12.9	-5.1%	11.6	-2.2%	12.3	4.3%	12.4	29.1%
	International Markets	8.0	-2.6%	11.4	41.3%	13.0	51.8%	8.2	-25.4%
VESICARE		3.7	-8.4%	3.6	-9.6%	4.1	-4.9%	3.2	-10.0%

- FY2022 sales of products in Japan are shown in a gross sales basis. FY2023 sales and forecasts are shown in a net sales basis, as in other regions.

- Established Markets: Europe, Canada, etc.

- Greater China: China, Hong Kong, Taiwan

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Australia, Export sales, etc.

- From FY2023 Q1, the commercial segment of some countries were changed from International Markets to Established Markets. All figures above reflect this change.

- PADCEV (United States): Co-promotion revenue from Pfizer

- Astellas' EVRENZO territories: Japan, Europe, the Commonwealth of Independent States, Middle East, South Africa, etc.

- VEOZAH: Approved as "VEOZA" in Europe

2) Revenue by region - FY2022 sales of products in Japan are shown in a gross sales basis. FY2023 sales and forecasts are shown in a net sales basis, as in other regions.

(1) Japan

Unit: B¥

<Global>	FY23							
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
XTANDI	14.4	2.3%	14.4	7.6%	15.3	3.4%	12.6	1.4%
PADCEV	2.2	13.1%	2.1	4.4%	2.2	-6.5%	2.0	-3.6%
XOSPATA	1.2	6.6%	1.1	4.2%	1.2	-7.1%	0.9	2.2%
EVRENZO	0.6	-12.1%	0.5	-10.8%	0.6	-13.9%	0.4	-16.3%
BETANIS	7.3	-21.3%	6.8	-16.5%	7.3	-18.3%	6.0	-17.1%
PROGRAF (Including GRACEPTOR)	8.0	-16.4%	7.3	-17.5%	8.2	-15.0%	6.0	-20.3%
HARNAL	0.4	-20.9%	0.3	-28.8%	0.4	-25.4%	0.2	-37.4%
<Main products>								
SUGLAT [Family]	7.4	-8.3%	7.1	-6.0%	7.5	-8.2%	6.0	-9.6%
SUJANU	2.9	-11.1%	2.7	-11.1%	3.0	-8.9%	2.4	-11.7%
REPATHA	1.7	1.5%	1.7	6.2%	1.9	8.6%	1.5	4.4%
LINZESS	1.7	-9.1%	1.6	-9.2%	1.8	-6.8%	1.4	-10.3%
BLINCYTO	2.4	33.4%	2.6	34.6%	3.3	43.9%	2.9	58.5%
EVENITY	11.5	15.1%	12.0	18.3%	13.2	16.5%	12.1	13.8%
SMYRAF	0.6	0.2%	0.6	-3.7%	0.7	0.1%	0.5	-12.5%
Vaccines	0.0	0.9%	3.2	0.8%	1.2	-54.4%	0.2	-147.6%
CIMZIA	2.6	-12.7%	2.6	-7.9%	2.6	-13.2%	2.2	-10.2%
Total Rx Sales In Japanese market	68.0	2.3%	69.0	5.3%	73.2	3.5%	58.8	2.7%



## (2) United States

Unit: M\$

		FY23							
		APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
		(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Revenue		1,092	-11.9%	1,084	-10.3%	1,185	-3.0%	1,227	7.1%
	XTANDI	632	-2.3%	654	-0.5%	703	5.3%	637	15.7%
	PADCEV	76	35.1%	87	76.9%	109	96.4%	148	172.4%
	XOSPATA	52	13.6%	48	0.5%	48	-11.5%	50	21.8%
	VEOZAH	4	-	5	-	16	-	25	-
	IZERVAY	-	-	8	-	28	-	47	-
	MYRBETRIQ	190	-0.3%	156	-4.4%	146	-10.5%	210	6.9%
	PROGRAF	17	-11.6%	18	-4.3%	18	-17.2%	16	-17.5%
	AMBISOME	25	-13.9%	26	-7.8%	33	13.5%	22	-31.8%
	CRESEMBA	62	18.6%	63	17.9%	69	26.1%	65	-3.5%
	LEXISCAN	29	-84.9%	17	-90.5%	12	-93.1%	7	-96.1%

## (3) Established Markets

Unit: M€

		FY23							
		APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
		(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Revenue		647	3.3%	651	1.9%	675	0.6%	678	10.0%
	XTANDI	365	7.7%	366	1.7%	373	1.1%	374	10.7%
	PADCEV	16	79.3%	17	76.7%	27	84.8%	34	126.4%
	XOSPATA	22	14.9%	25	19.1%	25	11.8%	25	7.0%
	VEOZA	-	-	-	-	-	-	1	-
	EVRENZO	2	345.9%	3	147.7%	4	147.8%	4	185.6%
	BETMIGA	77	5.2%	81	6.1%	83	3.3%	86	15.8%
	PROGRAF	119	-8.2%	115	-6.9%	121	-4.4%	116	0.5%
	OMNIC	16	-7.8%	17	0.7%	18	-1.2%	16	-5.7%

- Established Markets: Europe, Canada, etc.

- From FY2023 Q1, the commercial segment of some countries were changed from International Markets to Established Markets. All figures above reflect this change.

## (4) Greater China

Unit: B¥

		FY23							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Revenue		22.5	-2.7%	22.4	2.3%	22.4	11.4%	21.2	42.5%
	XTANDI	4.4	22.6%	5.7	135.3%	3.4	-11.4%	3.4	177.7%
	PADCEV	-	-	0.0	-	0.2	-	0.3	-
	XOSPATA	0.6	22.9%	0.7	-65.4%	1.7	-	0.3	-
	BETMIGA	1.0	-3.4%	0.9	-11.5%	1.0	-7.0%	1.1	20.8%
	PROGRAF	12.9	-5.1%	11.6	-2.2%	12.3	4.3%	12.4	29.1%
	HARNAL	2.0	-15.4%	2.0	-21.2%	2.4	30.1%	2.4	58.9%
	FEBURIC	0.8	0.4%	0.9	-4.6%	1.0	17.8%	0.9	13.0%

- Greater China: China, Hong Kong, Taiwan

## (5) International Markets

Unit: B¥

		FY23							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Revenue		34.7	2.4%	39.9	17.5%	44.2	21.6%	40.3	2.9%
	XTANDI	13.8	-1.0%	14.8	15.2%	17.5	26.4%	19.5	29.8%
	PADCEV	0.1	-	0.1	621.6%	0.3	442.2%	0.4	-
	XOSPATA	0.9	155.3%	0.8	36.4%	1.1	51.2%	1.1	78.8%
	EVRENZO	0.0	-	0.1	169.5%	0.1	437.6%	0.2	67.8%
	BETMIGA	3.4	19.3%	3.5	18.0%	4.0	28.6%	3.4	17.7%
	PROGRAF	8.0	-2.6%	11.4	41.3%	13.0	51.8%	8.2	-25.4%
	HARNAL	4.3	5.0%	4.7	2.5%	4.6	-2.0%	4.8	8.1%

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Australia, Export sales, etc.

- From FY2023 Q1, the commercial segment of some countries were changed from International Markets to Established Markets. All figures above reflect this change.

## R&D Pipeline

The list shows the development status in the target diseases for which we aim to obtain approval in Japan, the United States, Europe and/or China.

As of Apr 2024

Underlined items indicate changes from the previous announcement in Feb 2024.

### XTANDI and Strategic products (1/2)

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
enzalutamide MDV3100 (XTANDI)	Small molecule	Androgen receptor inhibitor	Metastatic castration-sensitive prostate cancer	China Filed (Sep 2023)	Pfizer	
			Non-metastatic castration-sensitive prostate cancer	<u>Europe</u> <u>Approved (Apr 2024)</u>		
enfortumab vedotin ASG-22ME (PADCEV)	Antibody-drug conjugate (ADC)	Nectin-4 targeted ADC	Metastatic urothelial cancer, platinum-containing chemotherapy and PD-1/L1 inhibitor pretreated	China Filed (Mar 2023)	In-house [Co-development with Pfizer]	
			Metastatic urothelial cancer, previously untreated (first line; combo with pembrolizumab)	Europe Filed (Jan 2024) Japan Filed (Jan 2024) <u>China</u> <u>Filed (Mar 2024)</u>		
			Muscle-invasive bladder cancer (combo with pembrolizumab)	P-III		
			Other solid tumors	P-II		
			Non-muscle-invasive bladder cancer	P-I		
gilteritinib ASP2215 (XOSPATA)	Small molecule	FLT3 inhibitor	Post-chemotherapy maintenance acute myeloid leukemia	P-III	In-house	
			Post-hematopoietic stem cell transplant maintenance acute myeloid leukemia	P-III		
			Newly diagnosed acute myeloid leukemia with high intensity induction of chemotherapy	P-III		
			Newly diagnosed acute myeloid leukemia with low intensity induction of chemotherapy	P-I		
			Acute myeloid leukemia in pediatric patients	P-III		

**XTANDI and Strategic products (2/2)**

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
<b>zolbetuximab</b> <b>IMAB362</b> <b>(VYLOY)</b>	Antibody	Anti-Claudin 18.2 monoclonal antibody	Gastric and gastroesophageal junction adenocarcinoma	Japan <u>Approved (Mar 2024)</u> US Filed (Jul 2023) Europe Filed (Jul 2023) China Filed (Jul 2023)	In-house (Ganymed)	
			Pancreatic adenocarcinoma	P-II		
<b>fezolinetant</b> <b>ESN364</b> <b>(VEOZAH***)</b>	Small molecule	NK3 receptor antagonist	Vasomotor symptoms due to menopause	China P-III Japan P-III	In-house (Ogeda)	
			<u>Induced vasomotor symptoms in breast cancer patients on adjuvant endocrine therapy</u>	P-III		
<b>avacincaptad pegol</b> <b>(IZERVAY)</b>	Pegylated RNA aptamer	Complement C5 inhibitor	Geographic atrophy secondary to age-related macular degeneration	Europe Filed (Aug 2023)		
			Stargardt disease	P-II		
<b>resamirigene bilparovec</b> <b>AT132</b>	Gene therapy (AAV-based gene therapy)	MTM1 gene replacement to express myotubularin	X-linked myotubular myopathy	P-II	In-house (Audentes Therapeutics)	
<b>roxadustat</b> <b>ASP1517/FG-4592</b>	Small molecule	HIF-PH inhibitor	Anemia associated with chronic kidney disease in pediatric patients	Europe P-III	FibroGen	Astellas has rights in Japan, Europe, the Commonwealth of Independent States, the Middle East, and South Africa.

\* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

\*\* Compounds with "In-house" in this column include ones discovered by collaborative research.

\*\*\* Approved as "VEOZA" in Europe.

**Updates from the previous announcement (Feb 2024):**

**enzalutamide:** Removed the description of the approval in US for non-metastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis in Nov 2023. Approved in Europe in Apr 2024 for high risk biochemical recurrent non-metastatic hormone sensitive prostate cancer that is unsuitable for salvage radiotherapy.

**enfortumab vedotin:** Removed the description of the approval in US for locally advanced or metastatic urothelial cancer in the first-line setting in Dec 2023. Filed in China in Mar 2024 for locally advanced or metastatic urothelial cancer in the first-line setting.

**zolbetuximab:** Approved in Japan in Mar 2024 for CLDN18.2 positive, unresectable, advanced or recurrent gastric cancer.

**fezolinetant:** Removed the description of the approval in Europe for moderate to severe vasomotor symptoms associated with menopause in Dec 2023. Entered into Phase 3 for induced vasomotor symptoms in breast cancer patients on adjuvant endocrine therapy.

Projects with Focus Area approach (1/2)

Primary Focus	Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensors **	Remarks
Immuno-oncology	ASP1570	Small molecule	DGKζ inhibitor	Cancer	P-I	In-house	
	ASP2138	Antibody	Anti-Claudin 18.2 and anti-CD3 bispecific antibody	Gastric and gastroesophageal junction adenocarcinoma, pancreatic adenocarcinoma	P-I	Xencor [Discovered through collaborative research]	
	ASP1002	Antibody	Bispecific antibody	Cancer	P-I	In-house	
	ASP1012	Oncolytic virus	Oncolytic virus encoding leptin-IL-2	Cancer	P-I	KaliVir	
	ASP2802	<u>Cell therapy</u>	<u>Autologous CD20 convertible CAR-T</u>	<u>B-cell lymphoma</u>	<u>P-I</u>	<u>In-house (Xyphos Biosciences)</u>	
Blindness and Regeneration	ASP7317	Cell therapy	Retinal pigment epithelium cells	Geographic atrophy secondary to age-related macular degeneration	P-I	In-house (Ocata Therapeutics)	

**Projects with Focus Area approach (2/2)**

Primary Focus	Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensors **	Remarks
Genetic regulation	resamirigene biparvovec AT132 ***	Gene therapy (AAV-based gene therapy)	MTM1 gene replacement to express myotubularin	X-linked myotubular myopathy	P-II	In-house (Audentes Therapeutics)	
	zocaglusagene nuzaparvovec AT845	Gene therapy (AAV-based gene therapy)	GAA gene replacement to express GAA enzyme	Pompe disease	P-I	In-house (Audentes Therapeutics)	
	ASP2016	Gene therapy (AAV-based gene therapy)	FXN gene replacement to express frataxin	Cardiomyopathy associated with Friedreich Ataxia	P-I	In-house (Audentes Therapeutics)	
Targeted Protein Degradation	ASP3082	Small molecule	KRAS G12D degrader	Cancer	P-I	In-house	
	ASP4396	Small molecule	KRAS G12D degrader	Cancer	P-I	In-house	

\* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

\*\* Compounds with "In-house" in this column include ones discovered by collaborative research.

\*\*\* AT132 is also listed in "XTANDI and Strategic products".

**Updates from the previous announcement (Feb 2024):**

**ASP2074:** Discontinued the development for cancer in Phase 1.

**ASP2802:** Entered into Phase 1 for B-cell lymphoma.

**ASP0367:** Discontinued the development for primary mitochondrial myopathies in Phase 2 and Duchenne muscular dystrophy in Phase 1 based on its clinical data.

**ASP2016:** Entered into Phase 1 for cardiomyopathy associated with Friedreich Ataxia.

**ASP4396:** Entered into Phase 1 for cancer.

**Others**

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
mirabegron YM178	Small molecule	β <sub>3</sub> receptor agonist	Neurogenic detrusor overactivity in pediatric patients	Europe P-III	In-house	
peficitinib ASP015K	Small molecule	JAK inhibitor	Rheumatoid arthritis	China Filed (Aug 2022)	In-house	
abiraterone decanoate PRL-02/ASP5541	Small molecule	CYP17 lyase inhibitor	Prostate cancer	P-I	In-house (Propella Therapeutics)	

\* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

\*\* Compounds with "In-house" in this column include ones discovered by collaborative research.

**Updates from the previous announcement (Feb 2024):**

**isavuconazole:** Removed the description of approval in US for invasive aspergillosis and invasive mucormycosis in pediatric patients in Dec 2023.

## Rx+ Program

As of Apr 2024

Underlined items indicate changes from the previous announcement in Feb 2024.

Category	Program	Concept	Status*	Partner	Remarks
Digital health Other services	BlueStar	Digital therapeutics for adults with diabetes	<u>Pivotal study (Japan)</u>	Welldoc Roche Diabetes Care Japan	
	Z1608	Digital therapeutic plus remote patient monitoring for heart failure	Under development	Welldoc Eko	
Drug-device combination	pudexacinium chloride ASP5354	Intraoperative ureter visualization for use in patients undergoing minimally invasive and open abdominopelvic surgeries	P-III	Stryker	

\* The list shows the most advanced stage if the stages are different depending on the region.

### Updates from the previous announcement (Feb 2024):

BlueStar: Entered into pivotal study in Japan.